Ishani Maharaj of Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
|Articles|March 1, 2002
- Pharmaceutical Technology-03-02-2002
- Volume 26
- Issue 3
Overview of Technologies Supporting Security Requirements in 21 CFR Part 11, Part II
Author(s)Orlando López
Current security technologies and associated infrastructures are designed to protect information assets and satisfy 21 CFR Part 11 requirements for integrity and privacy of records using authentication and encryption methods.
Advertisement
Articles in this issue
over 24 years ago
Outsourcing Outlookover 24 years ago
Developing Custom Adhesive Systems for Transdermal Drug Deliveryover 24 years ago
PDA Task Force Issues Guidelines to Aid Isolator Usersover 24 years ago
Drug Safety Concerns Shape Manufacturing Policyover 24 years ago
Production Information Mangementover 24 years ago
Validation Changes to the USP Assay Method for Ibuprofen Tabletsover 24 years ago
Systematic Troubleshooting for LC/MS/MSAdvertisement
Related to this article
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Jaenisch, Muraru, and Pandey join PharmTech's Cole to discuss FDA's generative AI paper, ARPA-H's SURPASS trials, and AI accountability.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
2
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
3
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
4
PharmTech AI Pulse Check: AI Watermark Vulnerability
5